Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with or without Microwave Ablation in Advanced NSCLC
NCT04102982Phase 2Unknown
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Nov 2019
- Primary completion
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of camrelizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Overall Survival at 24 months. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04102982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04102982.